XML 48 R4.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:    
Research and development expenses $ 492 $ 694
General and administrative expenses (Note 12a) 2,678 2,936
Operating loss (3,170) (3,630)
Financial income (expense), net (Note 12b) (280) 351
Net loss (3,450) (3,279)
Addition to net loss (for EPS purpose)    
Deemed dividend with respect to the repurchase of right for future investment (185) (292)
Deemed dividend due to exercise price adjustment of warrants as a result of certain down-round anti-dilution protection or price protection features included in the warrants (267)
Net loss applicable to stockholders of Common Stock (3,902) (3,571)
Comprehensive loss $ (3,450) $ (3,279)
Basic and diluted net loss per share $ (0.36) $ (0.61)
Weighted average number of shares of common stock used in computing basic and diluted net loss per share 10,519,682 5,649,262